<DOC>
	<DOCNO>NCT01060150</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , tolerability effect Osmotic Release Oral System ( OROS ) methylphenidate hydrochloride ( HCl ) learn skill change Korean participant Attention-Deficit Hyperactivity Disorder ( ADHD ) .</brief_summary>
	<brief_title>An Efficacy Study Osmotic Release Oral System ( OROS ) Methylphenidate Participants With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>This 12 week , open label ( people involve know identity intervention ) , prospective ( study follow participant forward time ) , single arm , multicenter study ( one hospital medical school team work medical research study ) OROS methylphenidate HCl . The study consist 6 visit Screening , Baseline , Week 1 , 3 , 6 12 . The participant already ADHD medication addition methylphenidate require undergo washout period ( period receive treatment ) least 1 week . The participant daily study medication start 18 milligram per day ( mg/day ) participants less 30 kilogram ( kg ) body weight 27 mg/day participant 30 kg . The dose increase 9 mg 18 mg every week Week 6 base treatment efficacy tolerability , follow maximum maintenance dose 72 mg orally daily Week 12 , dose decrease 9 mg depend tolerability . Efficacy primarily assess use Clinical Global Impression Severity Illness ( CGI-S ) scale , Clinical Global Impression Improvement Illness ( CGI-I ) scale , Korean version ADHD-IV Rating Scale ( K-ARS ) Learning Skill Test ( LST ) score . Participants ' safety monitor .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Participants must meet Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) criterion Attention Deficit Hyperactivity Disorder ( ADHD ) consider require medication therapy Participants agree observe visit schedule willingly complete evaluation define participant ( possibly complete parents/guardians ) treatment period Participants parents/guardians able understand participation procedure research spontaneously request discontinuation therein time Participants offer spontaneous consent participation Participants whose guardian/legal representative provide spontaneous write consent Hypersensitivity methylphenidate HCl Participants diagnose major depression anxiety disorder accord DSMIV Diagnostic criterion require drug therapy Participants history bipolar disorder , psychotic disorder , substance abuse disorder ordiagnosed overall developmental disorder , organic brain disorder , seizure ( sudden , uncontrolled muscle spasm loss consciousness result abnormal brain function ) disorder , movement disorder require medication therapy , family history Tourette 's syndrome ( neuropsychological disorder cause mark distress significant impairment social , occupational , important area function ) Taken Osmotic Release Oral System ( OROS ) Methylphenidate within 3 month prior screen Currently take alpha2 adrenergic receptor agonist , antidepressant , antipsychotic , benzodiazepine , modafinil , anticonvulsant ( drug use stop seizure ) health food supplement may central nervous system activity</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>Methylphenidate hydrochloride</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>CONCERTA</keyword>
</DOC>